Loading...
Loading...
Celgene Corporation
CELG today announced that the addition of
bortezomib to REVLIMID (lenalidomide) and low-dose dexamethasone (RVd),
the standard of myeloma therapy, significantly improved progression-free
survival (PFS) compared to lenalidomide and low-dose dexamethasone (Rd)
in patients newly-diagnosed with multiple myeloma. The phase 3 study was
conducted by SWOG, a publicly funded international cancer clinical
trials network and presented at the 57th American Society of
Hematology Annual Meeting.
In the 471-patient study, patients receiving RVd achieved a median PFS
of 43 months compared to a median PFS of 30 months for patients who
received Rd alone (HR = 0.712, 96% CI, one-sided p=0.0018 (two-sided
p=0.0037)). The data also show that overall survival (OS) was improved
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in